Morgan Stanley Says Risks Remain On Amylin

According to Morgan Stanley, Amylin Pharmaceuticals AMLN risks remain. Morgan Stanley said that it believes the latest update on the ongoing Amylin/Lilly legal battle accentuates the risks to Amylin. “While this decision is not on the breach of contract, we see most outcomes of that decision, discussed below, as potentially negative for Amylin.” Amylin Pharmaceuticals closed yesterday at $12.93.